Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan

被引：0

作者：

Chikashi Yoshida

Linda Fletcher

Kazuteru Ohashi

Hisashi Wakita

Takashi Kumagai

Masayuki Shiseki

Kousei Matsuei

Koiti Inokuchi

Yoshihiro Hatta

Yukari Shirasugi

Toshikazu Yamaguchi

Junichi Sakamoto

Susan Branford

Hisashi Sakamaki

机构：

[1] National Hospital Organization Mito Medical Center,Department of Hematology

[2] University of Adelaide,SA Pathology and School of Medicine

[3] Tokyo Metropolitan Cancer and Infectious Diseases Center,Hematology Division

[4] Komagome Hospital,Division of Hematology and Oncology

[5] Japanese Red Cross Society,Department of Hematology

[6] Narita Red Cross Hospital,Department of Hematology

[7] Ohme Municipal General Hospital,Division of Haematology/Oncology, Department of Medicine

[8] Tokyo Women’s Medical University Hospital,Division of Hematology, Department of Internal Medicine

[9] Kameda General Hospital,Department of Hematology and Rheumatology

[10] Nippon Medical School,Division of Hematology, Department of Internal Medicine

[11] Nihon University School of Medicine,Department of Special Analysis

[12] Tokai University School of Medicine,Graduate School of Medicine, Health and Community Medicine

[13] Biomedical Laboratories,undefined

[14] Inc.,undefined

[15] Nagoya University Graduate School of Medicine,undefined

来源：

International Journal of Clinical Oncology | 2012年 / 17卷

关键词：

Chronic myeloid leukemia; -; Real-time quantitative PCR; International scale; Conversion factor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：584 / 589

页数：5

共 52 条

[1]

Goldman JM(2003)Chronic myeloid leukemia—advances in biology and new approaches to treatment N Engl J Med 349 1451-1464

[2]

Melo JV(2009)Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 6041-6051

[3]

Baccarani M(2003)Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423-1432

[4]

Cortes J(2010)Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood 116 3758-3765

[5]

Pane F(1998)Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR Br J Haematol 102 768-774

[6]

Hughes TP(1999)Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics Br J Haematol 107 587-599

[7]

Kaeda J(2007)Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations J Mol Diagn 9 421-430

[8]

Branford S(2006)Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 28-37

[9]

Hughes TP(2004)Comparison of “log reduction from median pretherapeutic value” vs ratio BCR-ABL/ABL to express the therapeutic response in CML patients ASH annual meeting abstracts 104 1013-3338

[10]

Hochhaus A(2008)Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood 112 3330-491

← 1 2 3 4 5 6 →